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Abstract Site directed mutagenesis/charged-to-alanine sca ning mutagenesis of the amino terminal portion of human ERK2 (from amino acids 1 
to 150) purified as a glutathione-S-transferase fu ion protein (GST-ERK2) from E. coli has been done to determine regions/amino acids important 
for activation by rabbit skeletal muscle MAP kinase kinase (rMEK) and kinase activity towards myelin basic protein (MBP). Five classes of mutants 
have been isolated. The first class of mutants comprises of G30A/G32A, A50D and R65A/R68A/E69A, that can be phosphorylated by rMEK and 
have no kinase activity towards M BP, the second class includes mutants D122A/H 123A and N142A which have lower kinase activities but no change 
in their activation by rMEK; third class being Y34A, E58A/H59A, which have neutral effect owards either activity, the fourth class that includes 
completely inactive mutants D42A/K46A/R48A, the deletion mutant in the same region (-9aa[40-48]) and D104A/E107A/D109A and finally the 
fifth class that include K53A, E94A/K97AJD99A, K112A/K115A and R133AJK136A that are phosphorylated 140-240% but with kinase activity 
toward MBP ranging from 50--100% of the wild type. 
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1. Introduction 
A high percentage ofhuman tumors, including tumors of the 
lung, pancreas, thyroid and colon, contain 'activating' muta- 
tions in the coding region of the guanine nucleotide binding 
protein ras [1,2]. The ras family of proto-oncogenes ncode 
21,000 Da molecular weight (p21) guanine nucleotide binding 
proteins that act as molecular switches, conveying signals from 
ligand activated tyrosine kinases (e.g. EGF, PDGF) to the 
serine/threonine kinase pathway (i.e. c-raf-l). A consequence 
of activating the ras pathway can be either proliferation [3] or 
cell cycle arrest and differentiation [4]. Recently it has been 
demonstrated, using both a genetic and biochemical pproach, 
that the ras proto-oncogene binds and leads to the activation 
of the c-raf-1 Ser/Thr kinase, which in turn can phosphorylate 
and activate MAP kinase kinase (MEK) [5-10]. MEK has both 
threonine as well as tyrosine kinase activity; the only known 
substrate for MEK are the mitogen activated protein kinases, 
MAP kinases [11]. There are at least wo members of this kinase 
family, also termed extracellular-sigual regulated kinases, 
p42MAPKERK2 and p44MAPKERK1 [12--14]. Upon phosphoryl- 
ation by MEK, the map kinases ERK1 and ERK2 translocate 
to the nucleus and phosphorylate ranscription factors, such as 
c-Myc [15] or c-Jun [16] which leads to transcriptional ctiva- 
tion of promoters that are responsive to these factors followed 
by either proliferation or developmental events. 
We have sought to determine, by a combination of site- 
directed mutagenesis/charged-to-alanine sca ning mutagenesis 
(replacing charged amino acids with alanine) [17] and in vitro 
biochemical analysis, which domain(s)/amino acids of ERK2 
are important for its interaction with one of its substrates, 
myelin basic protein (MBP) and also its activation by MAP 
kinase kinase. The goal would ultimately be to construct pep- 
tides to inhibit ERK2 kinase activity/ERK2 activation by 
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rMEK based on the data from mutagenesis studies. Specific 
inhibitors of the MAP kinase pathway (which will be equivalent 
to inhibiting the signal emanating from Ras) should be useful 
anti-proliferative agents. Our initial studies have focused on the 
amino-terminal portion of ERK2, from amino acid positions 
1 through 150 (Fig. 1). We have discovered five classes of 
mutants. The first are ERK2 mutants that can be 
phosphorylated by rMEK in vitro but are unable to phospho- 
rylate MBP, the second class of mutants are phosphorylated by
rMEK, and have reduced MBP phosphorylating activity, the 
third class are neutral, in that the mutation has no effect on 
biological activity of the ERK2, the fourth class being com- 
pletely inactive mutants and the fifth class being mutants which 
are highly phosphorylated by rMEK. 
2. Materials and methods 
2.1. Materials 
pGEX2T-ERK2 was a kind gift from Dr. Tim Bird (Immunex Corp. 
Seattle, Washington). Myelin basic protein (MBP), sodium orthovana- 
date, fl-glycerolphosphate w re purchased from Sigma Chemical Co. 
(St. Louis, MO, USA). All the protease inhibitors were from Boehrin- 
ger Mannheim Corp. (Indianapolis, IN, USA) Glutathione-Sepharose, 
Fast-flow Q Sepharose, MonoQ HR 10/10 were from Pharmacia 
(Piscataway, NJ, USA). All the oligonucleotides for the mutagenesis 
studies were synthesized by National BioSciences (Plymouth, MN, 
USA). 
2.2. Recombinant DNA methods 
Human ERK2 was mutagenized by polymerase chain reaction using 
the plasmid pGEX-2T/ERK2 (a kind gift from T. Bird, Immunex 
Corp.) as template. Oligonucleotides were designed to introduce Sail 
and NotI sites at 5' and 3' ends of the amplified fragments to enable 
cloning into the pGEX-4T vector. With this technique, two complemen- 
tary mutagenic primers were required. Two separate amplifications 
were required to generate the complete 1,072 kb ERK2 insert. For the 
first amplification, plasmid DNA containing the wild type insert was 
used as the template DNA. In general, one tube contained the reverse 
mutagenic primer plus the primer with the Sail (4TPI-1; CCAAAA- 
TCGGATCTGGTTCCGCGTGGTCGACCGGTCCGCGGGCAG) 
and the other tube contained the forward mutagenic primer and the 
primer with the NotI restriction site (4TP2-1; GTCAGTCACGATG- 
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CGGCCGCTTATTAAGATCTGTATCCTGGCT). After amplifica- 
tion, the PCR products were isolated on a 4% polyacrylamide g l. For 
the second amplification, the two mutagenic fragments were combined 
along with the 4TPI-1 and 4TP2-1 to produce the 1,072 bp ERK2 
fragment. The insert DNA was next digested with Sail and NotI fol- 
lowed by ligation to pGEX-4T digested with Sail and NotI. The ligation 
mixture was then transformed into E. coli DH5~. Individual colonies 
were selected for plasmid and DNA sequencing analysis to confirm the 
presence of the desired mutation. All cloning, bacterial plasmid isola- 
tion and recombinant DNA methods were followed as described in [18]. 
2.3. Expression and purification of wild type and mutant GST-ERKs 
The GST-ERKs were purified by the method of Smith and Johnson 
[19] with a few modifications. The pGEX-4T vectors harboring the 
GST-ERK2s were transformed into E. coli DH5e. The E. coli were 
grown at 37°C in Luria broth until the O.D. at 600 nm = 0.5-0.6 at 
which time isopropyl-jS-D-thiogalactopyranoside (IPTG; 0.1 mM) was 
added and growth continued for an additional 2h. The cells were then 
pelleted, washed once with PBS and then frozen at -80°C. The pellet 
was then suspended in sonication buffer (50 mM Tris-HCl, pH 7.5, 50 
mM NaC1, 1 mM DTT, 1 mM MgC12, 1 mM EGTA, 10/lg/ml aprot- 
inin, 10/zg/ml leupeptin, 10/zg/ml antipain, 0.2 mM PMSF), disrupted 
by an ultrasonication disruptor for 1 min and sedimented. After addi- 
tion of Triton X-100 to 1%, the lysate was loaded on a 10 ml gluta- 
thione-Sepharose column (Pharmacia). The column was washed with 
10 bed volumes of sonication buffer +1% Triton, until OD 280 nm was 
0. The GST-ERK2s were eluted with 5 mM glutathione in sonication 
buffer (pH 8.0) and analyzed by SDS-PAGE electrophoresis. The pu- 
rity of the proteins isolated was greater than 95%. Approximately 2-5 
mg of purified GST-ERK2 were recovered from 1 1 of bacteria. The 
fractions containing GST-ERK2 were pooled, concentrated in Cen- 
triprep 3 and dialyzed overnight against storage buffer (20 mM MOPS, 
pH 7.2, 25 mM fl-glycerophosphate, 10 mM EGTA, 0.1 mM sodium 
orthovanadate, 1 mM DTT, 50 mM NaC1, 20% glycerol). 
2.4. Purification of ERK activator (MAP kinase kinase or MAPKK or 
rMEK) from rabbit skeletal muscle 
Extracts were prepared from 750 g of rabbit skeletal muscle and 
purified as described previously [20,21] but with the following modifica- 
tions. Firstly, the homogenate was subjected to batchwise chromatog- 
raphy on Fast Flow Q-Sepharose and the MAP kinase activator was 
eluted with buffer (50 mM fl-glycerophosphate, 2 mM EGTA, 2 mM 
EDTA, 1 mM sodium orthovanadate, 1 mM benzamidine, 0.1 mM 
PMSF, 25 mM sodium fluoride, 1 mM sodium pyrophosphate, 0.1% 
2-mecaptoethanol) containing 0.4 M NaCI. The enzyme was then pre- 
cipitated with 60% ammonium sulfate, dialyzed extensively and then 
loaded on a MonoQ (HR 10/10) column. After washing with equilibra- 
tion buffer (25 mM Tris-HCl, pH 8.9, 1 mM EDTA, 5% (v/v) glycerol, 
0.02% (w/v) Brij 35, 1 mM benzamidine, 0.1% (v/v) 2-mercaptoethanol), 
the column was developed with 300 ml of linear gradient to 1 M NaC1 
and 3 ml fractions were collected at 2 ml/min. The active fractions which 
eluted as a single peak were pooled, pH adjusted to pH 7.5 and then 
frozen in aliquots at -80°C. 
2.5. Assay of MBP kinase activity of GST-ERK2 activated by MAP 
kinase kinase 
The conditions for the GST-ERK2 kinase assay were as described 
previously [20]. Briefly, inactive, recombinant GST-ERK2 (2.5 ¢tl; 0.1- 
1.0 ,ug) was incubated for 3 min at 30°C with 2.5/zl of MAP kinase 
activator (diluted 15-fold; 0.66/tg) fraction and the activation of GST- 
ERK2 was initiated with 2.5/tl of 20 mM magnesium acetate/0.8 mM 
unlabelled ATE Dilution buffer (25 mM Tris-HC1, pH 7.5, 1 mM 
EDTA, 5% (v/v) glycerol, 0.02% (w/v) Brij 35) replaced MAPKK in 
control incubations. After 20 min, the assay of MAP kinase was ini- 
tiated with 40/zl of 10 mg/ml myelin basic protein (MBP; 20 pg) in 30 
mM Tris-HCl, pH 7.4, 0.125 mM EGTA, 0.125 mM sodium orthova- 
nadate and 12.5 mM magnesium acetate/0.25 mM [Z-32P]ATP (3 x 105 
cpm/nmol). Assays were terminated by spotting 40/11 aliquots on to 2.5 
cm Whatman P81 phosphocellulose paper. The papers were washed 
4 times (5 min) with 180 mM phosphoric acid and then in acetone 
before counting in a scintillation counter. 
2.6. SDS-PAGE assay of ERK2 activation by MAPKK 
The activation reaction was carried out as above except hat MBP 
was omitted from the assay and 1 pM okadaic acid and 0.1 mM sodium 
orthovanadate w re included. The reaction was terminated by the addi- 
tion of 4 x sample buffer, and proteins were separated on 12% SDS- 
PAGE gels [22]. The proteins were immunoblotted onto nitrocellulose 
membranes and counted in a phosphorimager. 
3. Results and discussion 
3.1. Properties of  purified GST-ERK2 protein 
The GST-ERK2 protein migrated as a 68 kDa protein on a 
12% SDS-PAGE gel. The GST-ERK2 mutants were recovered 
from this procedure with equal yields and purity. The recombi- 
nant GST-ERK2 isolated from E. coli is inactive as a kinase and 
thus has very low MBP phosphotransferase activity. The incu- 
bation of GST-ERK2 for 20 rain with partially purified MAP 
kinase kinase from rabbit skeletal muscle (rMEK) resulted in 
a 100-fold increase in phosphorylation of the GST-ERK2 com- 
pared with the autophosphorylation f GST-ERK2 in its ab- 
sence. This MEK dependent phosphorylation has been shown 
to occur within the sequence Thr-Glu-Tyr on Map kinase 
(amino acid position 183 to 185) and it has been shown that 
phosphorylation of both the threonine as well as the tyrosine 
residue are necessary for full kinase activity [23,24]. Under the 
reaction conditions chosen, the activation of GST-ERK2 by 
rMEK as assessed by the SDS-PAGE assay (section 2) is linear 
for 80 min and the kinase activity of the activated GST-ERK2 
is linear for 30 min (Data not shown). 
3.2. Properties of  the mutant GST-ERK2 proteins 
As shown in Fig. 1 and Table 1, 14 mutants localized to the 
amino terminal of MAP kinase were constructed either singly 
or in combination. These mutant proteins, along with the wild 
type protein, were purified on glutathione Sepharose beads and 
phosphorylated in vitro with FPLC purified rabbit skeletal 
muscle rMEK as described above. As shown in Fig. 2, of the 
14 mutants analyzed by the kinase assay and SDS-PAGE assay 
to evaluate the ability of ERK mutant proteins to be 
phosphorylated by rMEK, the mutants G30A/G32A, A50D 
and R65A/R68A/E69A are phosphorylated 44%, 53% and 72% 
of the wild type and with diminished MBP kinase activity (4%). 
The consensus GIy-X-Gly-X-X-Gly is found in many nucleo- 
tide binding proteins in addition to protein kinases (25,26] and 
substitution of the first two glycines with a hydrophobic group 
such as alanine results in reduced activities thus confirming the 
importance of the glycines in ATP binding. Also the introduc- 
Table 1 
Mutations in human ERK2 
Wild type Mutant 
G30/G32 AA 
Y34 A 






D 104/E 107/D 109 AAA 
K112/K115 AA 
D 122/H 123 AA 
R133/K136 AA 
N142 A 
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Fig. 1. Mutations in human ERK2. Amino acid sequence of human ERK2 is shown. The catalytic domains are shown in Roman numerals. The 
residues that were mutated are underlined and shown in bold lettering. The phosphorylation sites in ERK2 are indicated by asterisks. 
tion of a charge with no change in the size, that is, substituting 
the invariant alanine with aspartic acid (A50D), close to the 
ATP binding lysine (K52), reduces phosphorylation by 50% 
with loss of kinase activity. A similar mutation, that is, intro- 
duction of charge in the case of rat ERK2 ($39D) in the ATP 
binding site, as shown by Robbin et al. [11] led to an increase 
in phosphorylation byrMEK with slightly reduced MBP kinase 
activity. With reference to the triple mutant, R65A/R68A/ 
E69A, it has been proposed, based on the X-ray crystal struc- 
ture of the unphosphorylated ERK2 that R65 and R68 would 
interact with phosphorylated Thr ls3 thus causing domain clo- 
sure leading to relief of the steric constraints to substrate bind- 
ing [27]. It would thus be expected that replacing them with 
alanine would prevent domain closure and subsequent sub- 
strate binding and therefore loss of MBP kinase activity. Our 
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Fig. 2. Comparison of MBP kinase and phosphorylation by rMEK activities of GST-ERK2 mutants (0.1/ag). Wild type GST-ERK2 (0.1/lg) activities 
is 100%. In case of MBP kinase activity it is nmol of phosphate incorporated and activation of ERK2 with rMEK was measured by SDS-PAGE 
assay and counted on a phosphorimager. 
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phosphorylated and therefore not denatured and has no kinase 
activity, confirms the presence of R65 and R68 at the active site 
of ERK2. The second class of mutants, D122A/H123A and 
N142A show reduced kinase activity with almost no change in 
their activation by rMEK. The above data also indicates that 
the domains required for phosphorylation by rMEK and for 
kinase activity are separable which would have important im- 
plications for inhibitor design. 
The third class of mutants include Y34A and E58A/H59A 
which show only 20-30% reduction in either activity compared 
to wild type ERK2. The fourth class of mutants are the com- 
pletely inactive mutants, D42A/K46A/R48A, adeletion mutant 
in the same region (-9aa(40-48)) and DI04A/EI07A/D109A. 
The complete loss of activity of the deletion mutant shows the 
importance of the distance between the GEGAYG box and the 
invariant Lysine 52. In addition, the nature of the amino acids 
within the spacing is equally critical as changing the amino 
acids to alanine (D42A/K46A/R48A) completely destroys the 
activities also. The X-ray crystal structure of the nucleotide 
bound ERK2 (MgATP-ERK2) [27] shows that the amino 
group (N6) of the adenine ring is hydrogen bonded to the 
backbone carbonyl group of Asp ~°4. The ribose 02'  and O3' 
hydroxyls form a hydrogen bonding network to Asp 1°9 and 
Lys lj2. So the loss in activity may be due to the changes in 
Asp ~°9 and not Asp ~°4. Clearly this mutation (D109A) elimi- 
nates these linkages uch that rMEK is unable to phosphorylate 
ERK2 and therefore has no kinase activity. 
Finally the mutants, K53A, E94A/K97A/D98A, K l l2A/  
K 115A and R 133A/K 136A exhibit increased phosphorylation 
by rMEK and either lower (50%) or similar kinase activity as 
wild type ERK2. 
Based on these data obtained from the mutagenesis studies 
described above, we constructed a series of peptides based on 
the ERK2 amino acid sequence. The peptides are currently 
being tested for their ability to inhibit rMEK activation of 
GST-ERK2 and GST-ERK2 dependent MBP phosphoryla- 
tion. Smaller peptides (4-8 amino acids) based on these will be 
tested in this assay to determine the minimal length required to 
maintain kinase inhibitory activity. After defining this relation- 
ship in more detail a peptidomimetic approach to design a more 
'drug' like molecule will be initiated. 
In conclusion, we have defined five classes of mutants in 
human ERK2 by classical mutagenesis studies. Additional mu- 
tants are in the process of being constructed in the remaining 
70% of the molecule. This will allow us to define other domains 
of ERK2 that may be amenable to inhibition by peptides or 
other molecules. Furthermore, some of the mutants described 
above, which were generated by substituting the amino acid 
alanine for the cognate wild type amino acid, will be further 
mutagenized by substituting other amino acids. This will allow 
us to determine if the mutant ERK2 biochemical phenotype is
dependent on alanine substitution or if other (e.g. more bulky 
or charged amino acids) have the same effect on the activity and 
presumably on the structure of ERK2. 
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